In more resource-rich settings, early risk stratification can also guide further testing with additional biomarkers (e.g., urine neutrophil gelatinase-associated lipocalin [NGAL]) that may further delineate individual risk profile or be used to subgroup patients into unique subphenotypes of AKI which could guide management [24–27]. The gene discussed is LCN2; the disease is acute kidney injury.